These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
132 related items for PubMed ID: 1784098
1. [Therapeutic efficacy of kanamycin and clofazimine combined with muramyl dipeptide against Mycobacterium intracellulare infection induced in mice]. Tomioka H, Sato K, Saito H. Kekkaku; 1991 Dec; 66(12):811-7. PubMed ID: 1784098 [Abstract] [Full Text] [Related]
2. [In vitro antimycobacterial activity of clarithromycin and its therapeutic efficacy against Mycobacterium intracellulare infection induced in mice]. Tomioka H, Sato K, Saito H. Kekkaku; 1993 Apr; 68(4):293-9. PubMed ID: 8497119 [Abstract] [Full Text] [Related]
3. [Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, administered at the different periods of infection in Mycobacterium intracellulare--infected mice]. Tomioka H, Sato K, Saito H, Hidaka T. Kekkaku; 1993 Oct; 68(10):631-5. PubMed ID: 8255070 [Abstract] [Full Text] [Related]
4. [Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, in Mycobacterium intracellulare infection induced in mice]. Saito H, Tomioka H, Sato K, Hidaka T. Kekkaku; 1994 Feb; 69(2):59-63. PubMed ID: 8126989 [Abstract] [Full Text] [Related]
5. Stimulation of non-specific resistance to infection by muroctasin. Otani T, Une T, Osada Y. Arzneimittelforschung; 1988 Jul; 38(7A):969-76. PubMed ID: 3056426 [Abstract] [Full Text] [Related]
6. Therapeutic efficacy of benzoxazinorifamycin, KRM-1648, in combination with other antimicrobials against Mycobacterium leprae infection induced in nude mice. Saito H, Tomioka H, Sato K, Dekio S. Int J Lepr Other Mycobact Dis; 1994 Mar; 62(1):43-7. PubMed ID: 8189088 [Abstract] [Full Text] [Related]
7. [Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, administered in various frequencies per week in Mycobacterium intracellulare-infected mice]. Tomioka H, Sato K, Saito H, Dekio S, Hidaka T. Kekkaku; 1993 Nov; 68(11):683-6. PubMed ID: 8264123 [Abstract] [Full Text] [Related]
8. [A study on the activity of clofazimine with antituberculous drugs against Mycobacterium tuberculosis]. Lu Y, Wang B, Zhao WJ, Zheng MQ, Li P, Fu L, Liang BW. Zhonghua Jie He He Hu Xi Za Zhi; 2010 Sep; 33(9):675-8. PubMed ID: 21092635 [Abstract] [Full Text] [Related]
9. [Studies on therapeutic efficacy of a new anti-tuberculous drug, benzoxazinorifamycin, against murine experimental mycobacterial infections: attempt at various regimens and protocols]. Tomioka H, Saito H. Kekkaku; 1994 Nov; 69(11):703-10. PubMed ID: 7837724 [Abstract] [Full Text] [Related]
10. [Effects of half-sized secretory leukocyte protease inhibitor and Chinese traditional medicines, yokuinin and mao-bushi-saishin-to, on therapeutic efficacies of benzoxazinorifamycin KRM-1648 against Mycobacterium avium complex infection induced in mice]. Sato K, Shimizu T, Tomioka H, Kawahara S. Kekkaku; 1998 Aug; 73(8):501-6. PubMed ID: 9780605 [Abstract] [Full Text] [Related]
11. General pharmacological properties of muroctasin. Kojima H, Hirohashi M, Kasai Y, Takasuna K, Fukumoto C, Akashi A. Arzneimittelforschung; 1988 Jul; 38(7A):1002-9. PubMed ID: 3190791 [Abstract] [Full Text] [Related]
12. Antigenicity study of muroctasin. Yamaguchi F, Hattori H, Wagai N, Tsukada W. Arzneimittelforschung; 1988 Jul; 38(7A):1034-7. PubMed ID: 3190797 [Abstract] [Full Text] [Related]
13. [Activities of clofazimine against Mycobacterium tuberculosis in vitro and in vivo]. Lu Y, Zheng MQ, Wang B, Zhao WJ, Li P, Chu NH, Liang BW. Zhonghua Jie He He Hu Xi Za Zhi; 2008 Oct; 31(10):752-5. PubMed ID: 19080601 [Abstract] [Full Text] [Related]
14. Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice. Ishihara C, Hamada N, Yamamoto K, Iida J, Azuma I, Yamamura Y. Vaccine; 1985 Dec; 3(5):370-4. PubMed ID: 2417426 [Abstract] [Full Text] [Related]
15. Acute and chronic polyarthritis induced by an aqueous form of 6-O-acyl and N-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in euthymic rats and athymic nude rats. Kohashi O, Kohashi Y, Shigematsu N, Ozawa A, Kotani S. Lab Invest; 1986 Sep; 55(3):337-46. PubMed ID: 3489128 [Abstract] [Full Text] [Related]
16. Mutagenicity studies of muroctasin. Shimada H, Hattori C, Sato T. Arzneimittelforschung; 1988 Jul; 38(7A):1031-3. PubMed ID: 3056424 [Abstract] [Full Text] [Related]
17. Subacute toxicity of muroctasin in mice and dogs. Ono Y, Iwasaki T, Sekiguchi M, Onodera T. Arzneimittelforschung; 1988 Jul; 38(7A):1024-7. PubMed ID: 3190795 [Abstract] [Full Text] [Related]
18. Chronic toxicity of muroctasin in mice. Ono Y, Sekiguchi M, Aihara K, Onodera T. Arzneimittelforschung; 1988 Jul; 38(7A):1028-30. PubMed ID: 3190796 [Abstract] [Full Text] [Related]
19. Augmentation by priming with interferon-gamma of the binding of a muramyl dipeptide derivative to macrophages resulting in synergistic macrophage activation. Nagao S, Sato K, Osada Y. Jpn J Cancer Res; 1987 Jan; 78(1):80-6. PubMed ID: 3102442 [Abstract] [Full Text] [Related]
20. Specific binding sites of muroctasin on murine macrophages. Akasaki M, Masayasu H, Tsukada W, Takegoshi T. Arzneimittelforschung; 1988 Jul; 38(7A):978-80. PubMed ID: 3190804 [Abstract] [Full Text] [Related] Page: [Next] [New Search]